Skip to main content
    E

    EyePoint, Inc (EYPT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.31
    +0.00 (+0.52%)

    Market Cap: $34.82M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    EyePoint, Inc (EYPT) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    EyePoint (EYPT) trades at 10.6x sales and 0.3x book value. Its P/S of 10.6x is above its 5-year median of 9.4x. Its forward P/E is 6.2x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E6.2x
    Price to sales10.6x
    Price to book0.3x
    EV/FCF0.2x
    PEGN/A
    FCF yield-1089.7%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 10.4% above 9.6x and its P/B is 93.8% below 4.8x.

    MultipleCurrent5-year median10-year median
    P/S10.6x9.4x9.6x
    P/B0.3x2.7x4.8x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 106 to 120 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 1.3x in 2020 to 40.8x in 2025. 2025 was the highest of those years.

    Year endPriceP/SP/B
    2025$18.2740.8x5.0x
    2024$7.459.7x1.4x
    2023$23.1119.6x3.7x
    2022$3.503.2x1.4x
    2021$12.249.6x2.2x
    2020$6.581.3x5.1x
    2019$15.508.0x19.9x
    2018$18.90N/A4.8x
    2017$10.8016.4x4.9x
    2016$17.1038.7x39.6x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About EYPT

    What is EYPT's forward P/E ratio?

    EyePoint has a forward P/E ratio of 6.2x.

    Is EYPT stock overvalued?

    GNG's valuation label for EYPT is Undervalued.

    What is EYPT's price to sales ratio?

    EyePoint has a price to sales ratio of 10.6x.